Posted by Michael Wonder on 02 Jun 2018
Lundbeck and Otsuka's Rxulti (brexpiprazole) receives positive opinion in EU from CHMP for the treatment of schizophrenia in adults
1 June 2018 - A final decision from the European Commission is expected within 67 days.
Lundbeck and Otsuka today announce that the CHMP of the EMA has issued a positive opinion on Rxulti (brexpiprazole) for the treatment of schizophrenia in adults.
Brexpiprazole is a once-daily second generation (atypical) oral antipsychotic; it provides a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors. Brexpiprazole exhibits high affinity for these receptors as well as for noradrenaline alpha1B/2C receptors.
